Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

    Not Recruiting
  • End date
    Jun 7, 2022
  • participants needed
  • sponsor
    ACADIA Pharmaceuticals Inc.
Updated on 31 March 2021
Becky Howell
Primary Contact
Adams Clinical (0.4 mi away) Contact
+71 other location


To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.

Condition Adjunctive Treatment of Major Depressive Disorder
Treatment Pimavanserin
Clinical Study IdentifierNCT04000009
SponsorACADIA Pharmaceuticals Inc.
Last Modified on31 March 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note